1-butyl-3-methylimidazolium acetate

We are 1-butyl-3-methylimidazolium acetate CAS:284049-75-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

English Name: 1-butyl-3-methylimidazolium acetate
Molecular Formula:  C10H18N2O2
Molecular Weight: 198.26
CAS No.: 284049-75-8
Purity: 99%
Technical Information

Appearance: Purity:
NMR: Passed null
Solubility: Insolubility:
Impurity content:
(1) Methylimidazole content: < 1000 ppm;
(2) Halogen content: < 1000 ppm;
(3) Water content: < 1000 ppm

Physics-Chemistry Properties

Melting point: 32℃ Decomposition temperature: 220℃
Conductivity: 1.1ms/cm Electrochemical window: 3.1V
Viscosity: 554cp Density: 1.02 g/cm3

Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts
1-butyl-3-methylimidazolium acetate

Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.Viniltriacetoxisilano CAS:4130-08-9 Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.21142-29-0 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).1-(3-Amino-2-hydroxyphenyl)ethanone CAS:70977-72-9 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation.

Related Products
Product Name
Methyl 2-chloropropionate View Details
2-ethylhexane-1-thiol View Details
2,4-bis(2-chlorophenyl)-5-(3,4-dimethoxyphenyl)-1-1H-imidazole View Details
Ethyl 3-Bromopropionate manufacturer Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate manufacturer 3-Amino-4-pyrazolecarbonitrile manufacturer perfluorobutyric acid Cas:375-22-4 manufacturer BOC-PHE-OBZL manufacturer